- Cytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB)
May 14, 2026 · globenewswire.com
Third Annual Muscle Biology-Focused Research Symposium Highlighting Recent Innovations in the Field SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company will host the third annual Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) on Friday, May 29, 2026 from 8:00 AM to 5:00 PM Pacific Time.
- CYTOKINETICS TO HOST ANNUAL SYMPOSIUM ON CONTEMPORARY LANDSCAPES IN MUSCLE BIOLOGY (CLIMB)
May 14, 2026
THIRD ANNUAL MUSCLE BIOLOGY-FOCUSED RESEARCH SYMPOSIUM HIGHLIGHTING RECENT INNOVATIONS IN THE FIELD SOUTH SAN FRANCISCO, CALIF., MAY 14, 2026 (GLOBE NEWSWIRE) -- CYTOKINETICS, INCORPORATED (NASDAQ: CYTK) TODAY ANNOUNCED THAT THE COMPANY WILL HOST THE THIRD ANNUAL CONTEMPORARY LANDSCAPES IN MUSCLE BIOLOGY RESEARCH SYMPOSIUM (CLIMB) ON FRIDAY, MAY 29, 2026 FROM 8:00 AM TO 5:00 PM PACIFIC TIME.
- Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
May 12, 2026 · globenewswire.com
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026 at 3:35 PM Eastern Time in New York, NY.
- CYTOKINETICS TO PARTICIPATE IN THE 2026 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE
May 12, 2026
SOUTH SAN FRANCISCO, CALIF., MAY 12, 2026 (GLOBE NEWSWIRE) -- CYTOKINETICS, INCORPORATED (NASDAQ: CYTK) TODAY ANNOUNCED THAT MEMBERS OF THE COMPANY MANAGEMENT TEAM WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 2026 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE ON TUESDAY, MAY 19, 2026 AT 3:35 PM EASTERN TIME IN NEW YORK, NY.
- Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026
May 11, 2026 · globenewswire.com
SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the presentation of new data reinforcing the clinical profile of MYQORZO® (aficamten) at the European Society of Cardiology (ESC) Heart Failure 2026 Congress. The presentations include new analyses from SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with oHCM; MAPLE-HCM, the Phase 3 clinical trial of aficamten compared to metoprolol in patients with symptomatic obstructive HCM (oHCM); and FOREST-HCM, the open-label extension trial of aficamten.
- CYTOKINETICS ANNOUNCES NEW DATA RELATED TO MYQORZO® (AFICAMTEN) AT ESC HEART FAILURE 2026
May 11, 2026
SOUTH SAN FRANCISCO, CALIF., MAY 11, 2026 (GLOBE NEWSWIRE) -- CYTOKINETICS, INCORPORATED (NASDAQ: CYTK) TODAY ANNOUNCED THE PRESENTATION OF NEW DATA REINFORCING THE CLINICAL PROFILE OF MYQORZO® (AFICAMTEN) AT THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) HEART FAILURE 2026 CONGRESS. THE PRESENTATIONS INCLUDE NEW ANALYSES FROM SEQUOIA-HCM, THE PIVOTAL PHASE 3 CLINICAL TRIAL OF AFICAMTEN IN PATIENTS WITH OHCM; MAPLE-HCM, THE PHASE 3 CLINICAL TRIAL OF AFICAMTEN COMPARED TO METOPROLOL IN PATIENTS WITH SYMPTOMATIC OBSTRUCTIVE HCM (OHCM); AND FOREST-HCM, THE OPEN-LABEL EXTENSION TRIAL OF AFICAMTEN.
- Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million
May 8, 2026 · globenewswire.com
SOUTH SAN FRANCISCO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of an underwritten public offering of 11,338,028 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 1,478,873 additional shares, at a price to the public of $71.00 per share, before underwriting discounts and commissions. The gross proceeds to Cytokinetics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cytokinetics, were approximately $805 million. All of the shares of common stock in the offering were sold by Cytokinetics.
- CYTOKINETICS ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK AND FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES FOR GROSS PROCEEDS OF $805 MILLION
May 8, 2026
SOUTH SAN FRANCISCO, CALIF., MAY 08, 2026 (GLOBE NEWSWIRE) -- CYTOKINETICS, INCORPORATED (NASDAQ: CYTK) TODAY ANNOUNCED THE CLOSING OF AN UNDERWRITTEN PUBLIC OFFERING OF 11,338,028 SHARES OF ITS COMMON STOCK, INCLUDING THE FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE UP TO 1,478,873 ADDITIONAL SHARES, AT A PRICE TO THE PUBLIC OF $71.00 PER SHARE, BEFORE UNDERWRITING DISCOUNTS AND COMMISSIONS. THE GROSS PROCEEDS TO CYTOKINETICS FROM THE OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES PAYABLE BY CYTOKINETICS, WERE APPROXIMATELY $805 MILLION. ALL OF THE SHARES OF COMMON STOCK IN THE OFFERING WERE SOLD BY CYTOKINETICS.
- Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock
May 6, 2026 · globenewswire.com
SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 9,859,155 shares of its common stock at a price to the public of $71.00 per share, before underwriting discounts and commissions. The gross proceeds to Cytokinetics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cytokinetics, are expected to be approximately $700 million. The offering is expected to close on May 8, 2026, subject to customary closing conditions. Additionally, Cytokinetics has granted the underwriters a 30-day option to purchase up to an additional 1,478,873 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in the offering will be sold by Cytokinetics.
- Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock
May 6, 2026 · globenewswire.com
SOUTH SAN FRANCISCO, Calif. , May 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 9,859,155 shares of its common stock at a price to the public of $71. 00 per share, before underwriting discounts and commissions. The gross proceeds to Cytokinetics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cytokinetics, are expected to be approximately $700 million.